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Global evaluation of influenza vaccination in children
indicates that current recommendations are not followed.
Most children at high risk for influenza-related complica-
tions do not receive the vaccine, and increased efforts are
needed to protect them. Furthermore, vaccinating healthy
infants 6–23 months of age and their close contacts should
be strongly encouraged. Vaccinations are recommended
for children with recurrent acute otitis media or recurrent
respiratory tract infections and possibly for healthy daycare
and school-age children because of the potential socioeco-
nomic implications of influenza. Issues that need to be
addressed include educating physicians and parents con-
cerning influenza-related illness and complications, cost-
effectiveness and safety of licensed vaccines, adequate
vaccine supply, and availability of intranasal products. 
I
nfluenza vaccination is routinely recommended in pedi-
atric patients of age >6 months who are at high risk for
influenza-related complications because they have an
underlying disease or are undergoing long-term aspirin
therapy and are at risk of developing Reye syndrome
(1–4). Administering the vaccine to healthy children is rec-
ommended only when they live with persons at high risk
(1–4), although the Advisory Committee on Immunization
Practices is gradually moving toward a recommendation to
vaccinate all children ages 6–23 months (because of their
substantially increased risk for influenza-related hospital-
izations) and children ages 2–18 years who are household
contacts of children ages 0<23 months (1–7). 
Although health authorities in industrialized countries
agree with these guidelines, use of influenza vaccine in
clinical practice differs. Most children at high risk for com-
plications do not receive the vaccine, and its use in healthy
infants is not routinely accepted (8–10), even though
results of recent studies suggest expanding the number of
children for whom vaccination should be recommended
(11–14). We discuss current vaccination practices in chil-
dren, reasons and possible remedies for low immunization
rates, and the possibility of extending its use in pediatrics.
Vaccine Practices for Children
High-risk children for whom influenza vaccination is
routinely recommended include those with chronic disor-
ders of the cardiovascular or pulmonary system (including
asthma), chronic metabolic diseases (including diabetes
mellitus), chronic renal dysfunction, and hemoglo-
binopathies or immunosuppression (including cases
caused by medications or by HIV) (1–4). Although an
association between these conditions and an increased risk
for influenza complications was first suggested many
years ago (15,16), the level of vaccination in such children
is still much lower than recommended, although it is
slightly higher when children are followed up in special-
ized centers rather than by primary care physicians (per-
haps because children seen in specialty clinics have more
severe underlying illnesses), or when data regarding
immunization are collected after implementing a reminder
and recall system (8–10,17–19). One study of health main-
tenance organizations reported influenza vaccination rates
of 9% to 10% among children with asthma and a rate of
25% among those attending an allergy and immunology
clinic (17). The use of a reminder and recall system
increased vaccination coverage among children with asth-
ma from 5% to 32% (18). The highest coverage was found
among pediatric patients attending a cystic fibrosis treat-
ment center, in whom a vaccination level of 79% was
reached (19). Data collected in Italy confirm that the
behavior of pediatricians is not in line with the official rec-
ommendations. Among the 274 high-risk children attend-
ing the University of Milan’s Pediatric Emergency
Department during winter 2002–2003, the vaccination
level was 26.3%; the highest rates were in children with
HIV infection (52.3%), and the lowest rates were in those
with asthma (9.5%) (10). 
Few data concern the effect of encouraging vaccina-
tion in healthy children <2 years. However, comparing
immunization rates among children of this age without
any high-risk condition attending the University of
Milan’s Pediatric Emergency Department during the two
winter seasons of 2001 to 2002 and 2002 to 2003 (after
the publication of the suggestion that healthy children <2
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(2.4% vs. 3.6%) (10).
Reasons for Low Immunization Rates 
and Possible Solutions
Seven main obstacles to complying with recommenda-
tions for vaccination in children exist: 1) lack of under-
standing of the risk for influenza complications in
children; 2) lack of knowledge of annual immunization’s
efficacy in primary prevention; 3) parents’ negative reac-
tion to parenteral vaccine administration (“Not another
shot!”); 4) need for two priming doses in children <9 years
old followed by annual administration; 5) fear of limited
protection in younger and high-risk children; 6) concerns
about possible adverse events; and 7) lack of precision in
current recommendations. The most important of these
obstacles are lack of understanding of the risks for compli-
cations and lack of knowledge of efficacy (10,20). 
A number of studies of adult (particularly elderly) pop-
ulations have shown that knowing risk factors for influen-
za complications, favorable perceptions of the vaccine,
and clinician recommendations are the main variables pre-
dicting the administration of influenza vaccination
(1,21,22). However, pediatric data indicate that some
providers do not recognize influenza’s clinical relevance,
even when it occurs in children with severe underlying dis-
ease (8,9). A study designed to ascertain the self-reported
use of influenza vaccine among pediatric oncologists
found that approximately 30% did not think that influenza
infection is important in children with cancer (8) and con-
sequently do not recommend immunization. The central
role of physicians’ opinions in determining vaccination
coverage is supported by data collected in a cross-section-
al study of a group of children hospitalized during the
influenza season in the United States (9): >70% of the chil-
dren were vaccinated if a physician had recommended it to
their parents, but 3% were vaccinated if no such recom-
mendation had been made. A lack of awareness that chil-
dren can receive influenza vaccine was a commonly cited
reason for nonvaccination (9).
The attitude of pediatricians towards influenza vaccine
can be explained by the fact that its importance in high-risk
children and healthy infants is mainly suggested by indi-
rect data. Although a number of studies have shown that
influenza can significantly increase hospitalization, outpa-
tient visits, and drug consumption in high-risk children of
all ages (15,16), few trials (mainly involving children with
asthma) have demonstrated that vaccination is clinically
useful in reducing influenza-related complications (23,24).
Furthermore, data concerning the efficacy of influenza
vaccine in healthy infants <2 years of age have been col-
lected from small groups. Although a reduction in influen-
zalike illnesses has been shown, the data do not evaluate
the importance of vaccination in reducing hospitalizations
or complications (25,26). Pediatricians may be definitive-
ly convinced of the importance of preventing influenza and
personally start supporting the use of vaccine when more
data are available demonstrating its efficacy in children.
Consequently, studies evaluating the real clinical impact of
influenza vaccine, not only in children with risk factors but
also in healthy infants, are needed. 
Another probable factor preventing the use of influenza
vaccines in pediatrics is that those currently licensed for
use in children are parenteral (two injections for children
<9 years of age being vaccinated for the first time) and
require annual administration to maintain protection
(1,3,27). Parents may be concerned about the number of
injections their children receive during the course of rou-
tine early child health visits. Given the large number of
vaccinations already included in the routine childhood
immunization schedule, the addition of another “shot” may
not sound attractive to parents and certainly not to their
children. However, the availability of intranasal influenza
vaccines may substantially reduce this problem (28).
Recent advances in influenza vaccination include the
development of a trivalent, cold-adapted, live-attenuated,
intranasal vaccine that appears to be as effective as its
intramuscular counterparts and induces a good immune
response (including local immunoglobulin [Ig] A respons-
es and secretory IgA antibodies that can protect against
pathogens infecting mucosal sites) (29). One of the disad-
vantages of this vaccine is that individual susceptibility to
infection with live viruses (and consequent immunogenic-
ity) varies widely; vaccine strains’ reversion to their wild-
type genotype has also been considered a potential risk,
although there is no evidence that this occurs (29). If even-
tually licensed for use worldwide, intranasal vaccines can
be expected to increase influenza vaccination coverage,
especially in children.
Concerns that influenza vaccine may offer limited pro-
tection and fears of possible adverse events are further rea-
sons for its limited use in pediatrics (20). However,
protective antibody levels after influenza vaccination have
developed in 70% to 90% of children as young as 6 months
of age, although fewer younger infants seroconvert, and
some high-risk children may have a lower antibody
response (1). Childhood vaccination programs fail to be
beneficial if vaccine efficacy falls to <25%, levels that
have never been reported in younger or high-risk children
(1). Moreover, although mild local and systemic reactions
to the vaccine may occur more frequently in persons who
have never been exposed to the viral antigens it contains
(e.g., young children), the currently licensed parenteral
vaccines are generally safe and well-tolerated (1).
Considering the possible effect that “vaccine-adverse” par-
ents have on immunization policy in some regions, dis-
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and immunogenicity of influenza vaccination in healthy
infants and high-risk children is important. 
Influenza prevention recommendations imprecisely
describe the characteristics of high-risk children, con-
tributing to inadequate vaccination in this population. For
example, the Advisory Committee on Immunization
Practices recommends yearly influenza vaccination for
immunosuppressed children, including those with
immunosuppression due to medications (1) but does not
specify which diseases require vaccination, the doses of
the immunosuppressive drugs, or the timing of the vacci-
nation in relation to their administration (1). Conversely,
the American Academy of Pediatrics states that the optimal
time to immunize these children is when their peripheral
leukocyte count is >1,000/µL and that vaccination has to
be deferred during high-dose corticosteroid administration
(27). These discrepancies reflect a lack of data and may
explain why pediatricians have different approaches in
clinical practice. Specific and uniform guidelines for each
group of children at high risk would be the best way to
overcome this problem. Still, in many clinical scenarios
decisions are based on the best information available, and
recommendations cannot deal with each and every situa-
tion that the medical provider confronts.
Globally evaluating the main reasons for low influenza
vaccination coverage in pediatrics suggests that improving
knowledge of influenza among pediatricians and parents
could improve vaccination practices. The medical commu-
nity spends substantial amounts of time with parents trying
to convince them of the need for routine vaccinations, but
in many instances, vaccines are suggested on the basis of
the parents’or the healthcare providers’perception of vac-
cine or diseases of greatest importance. If parents lack
insurance, economic considerations also become an issue.
A change of mindset is needed to enhance acceptance of
influenza vaccination; providing materials to educate par-
ents would help effect this change. As television and print
advertising promotes other pharmaceutical products, simi-
lar advertising could effectively promote influenza vacci-
nation. The first step is to define simple, unequivocal, and
practical guidelines specific to different groups of children
at high risk and healthy infants <2 years of age. These
guidelines, for distribution to hospital physicians and pri-
mary care pediatricians, would contain detailed informa-
tion regarding the consequences of influenza in such
children and describe the effectiveness of influenza vac-
cine and the risk for adverse events. In addition, pediatri-
cians can use recall systems to provide timely reminders
for all patients. 
Influenza Vaccine in Children Not at Risk
In addition to the children for whom influenza vaccine
is already recommended or strongly encouraged, other
pediatric patients can receive clinical benefits from its
use. One group of children who could be included on the
list of vaccination candidates is those with recurrent
episodes of acute otitis media (AOM). Recurrent AOM is
common in infants and children, and its possible sequelae
make prevention desirable (30). Until a few years ago,
chemoprophylaxis and controlling environmental risk fac-
tors were considered the best ways to reduce the incidence
of new episodes of AOM in otitis-prone children, but the
emergence of drug-resistant bacteria after antimicrobial
drug administration raises questions about the advisabili-
ty of drug therapy (13,30). Immunoprophylaxis against
respiratory viruses has received growing attention
because viral infections (including influenza) are associat-
ed with many, if not most, episodes of AOM. Data show-
ing that administering parenteral, inactivated influenza
vaccine can decrease the incidence of AOM by approxi-
mately one third strongly support the use of vaccination in
preventing AOM (31). The demonstration that live-atten-
uated, cold-adapted, intranasal vaccine causes a 30%
reduction in the incidence of febrile AOM in healthy chil-
dren without a history of ear disease leads to the same
conclusion (25). The importance of influenza vaccination
in children with recurrent AOM has been recently demon-
strated by Marchisio et al., who used an intranasal, inacti-
vated, virosomal subunit vaccine (13). In this study, 133
children aged 1–5 years with recurrent AOM (defined as
>3 episodes in the preceding 6 months or >4 episodes in
the preceding 12 months) were randomized to receive the
vaccine (n = 67) or no vaccination (n = 66). During a 6-
month period, 24 vaccine recipients (35.8%) experienced
32 episodes of AOM, and 42 control participants (63.6%)
experienced 64 episodes. The overall efficacy of vaccina-
tion in preventing AOM was 43.7% (95% confidence
interval 18.6 to 61.1, p = 0.002) (Table 1) (13). Moreover,
the cumulative duration of middle ear effusion was signif-
icantly less in the vaccinated children (58.0% vs. 74.5%;
p < 0.0001) (13). As reducing the occurrence of AOM in
children with recurrent episodes can have substantial clin-
ical and socioeconomic effects, these data suggest that
influenza vaccine can be considered a valid option in pre-
venting the disease in otitis-prone children.
A second group of children who could be considered
for influenza vaccine are those with recurrent episodes of
respiratory tract infections (RRTIs). A large number of
children without any immunologic problems experience
multiple episodes of RRTIs during the first years of life;
although these generally have a benign prognosis, they can
cause substantial medical and socioeconomic problems
(32). They are mainly caused by viruses and, during epi-
demic periods, influenza viruses can also be causative.
Data collected in a recent study indicate that vaccinating
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decreasing respiratory-related illness among them and
their families (14). A total of 127 children 6 months to 9
years of age with a history of RRTIs (>6 episodes per year
if >3 years; >8 episodes per year if <3 years) were random-
ized to receive the intranasal virosomal influenza vaccine
(n = 64 with 176 household contacts) or a control placebo
(n = 63 with 173 household contacts). During the influen-
za season, vaccinated children had fewer respiratory infec-
tions or febrile respiratory illnesses, received fewer
prescribed antimicrobial and antipyretic drugs, and missed
fewer school days than the controls (Table 2); similar ben-
efits and a reduced loss of parental work were observed
among their household contacts (14). These results show
that the benefits of influenza vaccination extend to chil-
dren with RRTIs and their families and suggest that its use
in such children should be encouraged. 
Influenza Vaccine in Healthy Daycare 
and School-Aged Children
Anumber of studies have shown that otherwise healthy
daycare and school-aged children are most frequently
affected by influenza, and high attack rates can substantial-
ly diminish their quality of life and disrupt everyday activ-
ities (33–36). Children shed larger quantities of influenza
viruses for longer periods of time than adults and thus play
an important role in spreading infection in their families
and communities (1,37). Negative effects of influenza in
otherwise-healthy children can extend to unvaccinated
household contacts, who may require substantial diagnos-
tic and therapeutic interventions and miss a number of
school or working days. Neuzil et al. found that, during the
influenza season, the number of household members who
became ill within 3 days of a child’s absence from school
was 2.2 times higher than expected. Excess absenteeism
from work also occurred among parents (34). In line with
these observations, we have found that the household con-
tacts of children with influenza require more medical vis-
its, miss more working or school days, and need more help
at home to care for ill children than the household contacts
of children without influenza (36).
Preventing influenza by vaccination can improve these
situations. A blinded, placebo-controlled study of two
influenza vaccines (an inactivated split-virus vaccine and a
live-attenuated, cold-adapted vaccine) in 555 school-aged
children in Russia demonstrated that both were efficacious
in preventing school absenteeism by reducing the number
of missed school days by 47% to 56% compared to missed
school days in unvaccinated children (38). Similarly, in a
study of the effect of an inactivated, split-virus vaccine on
healthy children attending daycare or school in Italy dur-
ing the years 2001–2002, we found that the vaccinated
children experienced fewer upper and lower respiratory
tract infections, received fewer antimicrobial and
antipyretic prescriptions, and missed fewer school days
because of respiratory illnesses (39). These data suggest
that the effect of influenza on otherwise-healthy daycare or
school-age children may be more substantial than is usual-
ly thought, encouraging wider pediatric use of influenza
vaccine to reduce the overall extent of infection.
Strong support for wider pediatric use comes from eval-
uating the household impact of influenza vaccination in
healthy daycare and school-age children. In a 1995 ran-
domized, controlled trial of influenza vaccine for preschool
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Table 1. Effectiveness of influenza vaccine as indicated by the occurrence of febrile respiratory illness and acute otitis media (AOM), 
and the use of antibiotics in children during the 6 months after vaccine administration
a 
Variable   Vaccine recipients, n = 67 (%)  Control participants, n = 66 (%)  Vaccine efficacy, %  p value 
Febrile respiratory illness  55 (82.1)  63 (95.5)  13.2  0.03 
>1 course of antibiotics  26 (38.8)  42 (63.6)  38.9  0.007 
>1 AOM episode   24 (35.8)  42 (63.6)  43.7  0.002 
>2 AOM episodes  6 (9.0)  16 (24.2)  63.1  0.03 
aModified from P. Marchisio et al. (13). 
Table 2. Respiratory illness among children with recurrent respiratory tract infections and effectiveness of the influenza vaccine during 
the follow-up period
a 
Event  Vaccinated children, n = 64
b  Controls, n = 63
b  Vaccine effectiveness, %
c  p value 
No. of upper respiratory tract infections  2.95 ± 1.33 (3)  4.06 ± 2.13 (4)  27  <0.0001 
No. of lower respiratory tract infections  0.67 ± 0.88 (0)  1.01 ± 1.12 (1)  33  0.03 
No. of febrile respiratory illnesses  1.60 ± 1.39 (1)  2.06 ± 2.14 (2)  23  0.02 
No. of hospitalizations  0.05 ± 0.10 (0)  0.10 ± 0.25 (0)  60  0.34 
No. of antimicrobial prescriptions  1.31 ± 1.33 (1)  2.35 ± 1.59 (2)  44  <0.0001 
No. of antipyretic prescriptions  2.16 ± 2.03 (2)  3.98 ± 2.37 (4)  45  <0.0001 
Missed school days  5.35 ± 8.14 (6)  13.83 ±12.50 (10)  61  <0.0001 
aModified from S. Esposito et al. (14).
 
bMean values ± standard deviation (median in parentheses).  
cVaccine effectiveness: 1 minus attack rate (defined as rate of illness divided by total population) among vaccinated children divided by attack rate among controls. children, the rate of febrile respiratory illnesses was 42%
less among the unvaccinated household contacts of
influenza-vaccinated children than among those living with
unvaccinated children (40). Moreover, data collected in
Tecumseh, Michigan (41), and Japan (7) indicate that mass
vaccination of school-age children correlates with a
reduced rate of respiratory illness and all-cause communi-
ty death rate, which suggests that larger scale immuniza-
tion can affect community epidemics. Similarly, during the
2001–2002 influenza season in Italy, we found that, com-
pared to the household contacts of unvaccinated children,
family members of influenza-vaccinated healthy children
experienced fewer respiratory tract infections, needed
fewer medical visits, missed fewer working days, and
required less help at home to care for ill children (Table 3)
(39). All of these findings highlight the fact that influenza
in otherwise-healthy children attending daycare centers or
schools has a considerable effect on their families and that
the benefits of influenza vaccination extend to the family
members of vaccinated persons.
The socioeconomic importance of influenza in child-
hood is confirmed by economic analyses showing that vac-
cinating healthy preschool and school-age children can
lead to health and economic benefits during epidemic and
pandemic periods (42–45). These studies used different
analytic methods, outcomes, and costs but came to a com-
mon conclusion: vaccinating healthy children against
influenza leads to a net cost saving, and the greatest finan-
cial benefit is observed when the vaccine is administered
in a group setting (42–45). Savings are primarily due to
avoided indirect costs and, in particular, reduced parental
absenteeism from work. 
Conclusion
Global evaluation of the effect of influenza in pediatric
patients indicates that influenza vaccination should be
more widely used than is usually recommended. To protect
them against the complications of influenza, increased
efforts are needed to identify and recall high-risk children.
Further, immunizing infants 6–23 months of age and their
close contacts is recommended. Children with recurrent
AOM or a history of RRTIs and healthy children attending
daycare centers or schools should also be included among
the pediatric groups recommended for vaccination. 
These conclusions are based on clinical and socioeco-
nomic considerations arising from evaluating the impact of
influenza vaccination on both the children themselves and
their household contacts. Improved recognition of the
complications of influenza in the first years of life, with
resources dedicated to provider and public education on
this issue, can help reduce obstacles to using influenza
vaccine. Parents might choose vaccination for their chil-
dren if they were more informed about the health and eco-
nomic cost of influenza, its annual attack rate in childhood
(which leads to days lost from school and work), and the
central role of children in disseminating the infection in
households and communities. The issues that need to be
addressed include educating physicians and parents about
the illness caused by influenza, the cost-effectiveness and
safety of licensed vaccines, adequate vaccine supplies, and
the availability of intranasal products. Improved compli-
ance associated with nasal administration should increase
the use of influenza vaccination. Only a heightened and
regular demand for influenza vaccine will result in suffi-
cient vaccine supplies at all times (not just on a year-to-
year basis) and place us in a better position to detect a
novel pandemic influenza virus strain. 
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Household contacts of 
vaccinated children (n = 728)
b 
Household contacts of 




c  p value 
No. of respiratory tract infections  3.03 ± 1.68  4.27 ± 1.68  30  0.0005 
No. of medical visits because of 
respiratory illness 
2.18 ± 1.37  3.16 ± 1.77  32  0.002 
Loss of maternal work, days  3.22 ± 1.86  4.78 ± 2.34  33  0.001 
Loss of paternal work, days  0.56 ± 0.46  0.98 ± 2.24  43  0.001 
Help at home to care for ill children, days  0.57 ± 0.37  3.22 ± 2.24  83  <0.0001 
aModified from S. Esposito et al. (39).
 
bMean values ± standard deviation.  
cVaccine effectiveness: 1 minus attack rate (defined as rate of illness divided by the total population) among household contacts of vaccinated children divided by attack 
rate among household contacts of controls. Istituti Clinici di Perfezionamento. Her main research activities
concern the epidemiology and prevention of infectious diseases
in childhood.
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